NCT04547101View on ClinicalTrials.gov

A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 24, 2020

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions
MSI-H/dMMR Solid Tumor
Interventions
DRUG

AK104

AK104，6 mg/kg IV，every 2 weeks (Q2W)

Trial Locations (1)

510000

Sun Yat-Sen University Cancer Center, Guangzhou

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
collaborator

Akeso Pharmaceuticals, Inc.

OTHER

lead

Akeso

INDUSTRY